Latanoprost
- Atc Codes:S01EE01
- CAS Codes:130209-82-4
- PHARMGKB ID:130209-82-4
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Latanoprost, Xalatan; Belgium: Xalatan; Bulgaria: Xalatan; Cyprus: Xalatan; Czech Republic: Latanoprost, Solusin, Unilat, Xalatan, Xaloptic; Denmark: Xalatan; Estonia: Glaumax, Latanoprost, Xalatan; Finland: Latanoprost, Xalatan; France: Xalatan; Germany: Latano-Q, Latanoprost, Xalatan; Greece: Latandrops, Lataneau, Latanoprost, Lataz, X-Iop, Xalaprost, Xalatan; Hungary: Xalatan; Ireland: Proxal, Xalatan; Italy: Xalatan; Latvia: Latanoprost; Lithuania: Latanoprost, Unilat, Xalatan, Xaloptic; Malta: Latanoprost, Xalatan; Netherlands: Latanoprost, Xalatan; Poland: Arrowprost, Latanoprost, Xalatan, Xaloptic; Portugal: Latanoprost, Oflex, Xalatan; Romania: Unilat, Xalatan, Xaloptic; Slovakia: Latanoprost, Solusin, Unilat, Xalatan, Xaloptic; Slovenia: Latanoprost, Xalatan; Spain: Latanoprost, Theaprost, Xalatan; Sweden: Latanoprost, Xalatan; UK: Xalatan.
North America
Canada: Xalatan; USA: Xalatan.
Latin America
Argentina: Glaucostat, Klonaprost, Latanoprost, Ocuprost, Tanamof, Xalatan; Brazil: Xalatan; Mexico: Algun, Gaap Ofteno, Kevixkeni, Latsol, Pioprost, Xalatan.
Asia
Japan: Xalatan.
Drug combinations
Latanoprost and Timolol
Chemistry
Latanoprost: C~26~H~40~O~5~. Mw: 432.59. (1) 5-Heptenoic acid, 7-[3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl]-1-methylethyl ester, [1R-[1α(Z),2β(R*),3α,5α]]-; (2) Isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate. CAS-130209-82-4 (1996).
Pharmacologic Category
Antiglaucoma Agents; Prostaglandin Analogs. Ophthalmic Prostaglandin. (ATC-Code: S01EE01).
Mechanism of action
Selective prostanoid agonist. Latanoprost is a prostaglandin F~2α~ analog. Appears to reduce intraocular pressure by increasing uveoscleral outflow of aqueous humor.
Therapeutic use
Reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension.
Pregnancy and lactiation implications
Embryocidal in rabbits. There are no adequate studies in pregnant women. Should be used during pregnancy only when potential benefits justify possible risks to fetus. Unknown whether latanoprost or its metabolites are distributed into milk following topical application to eye (use with caution in nursing women).
Unlabeled use
Contraindications
Hypersensitivity to latanoprost or any component of the formulation.
Warnings and precautions
Inadvertent contamination of multiple-dose ophthalmic solutions caused bacterial keratitis. May permanently change/increase brown pigmentation of iris, eyelid skin, and eyelashes. May increase length and/or number of eyelashes (may vary between eyes). Long-term consequences and potential injury to eye unknown. Use with caution in intraocular inflammation, aphakic patients, pseudophakic patients with torn posterior lens capsule, or risk factors for macular edema. Safety and efficacy not determined for use in angle-closure, inflammatory, or neovascular glaucoma. Remove contact lens prior to administration and wait 15 minutes before reinserting (contains benzalkonium chloride which may be adsorbed by contact lenses).